# Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations

> **NCT02450591** · NA · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 4 (actual)

## Conditions studied

- Oligometastatic Lung Adenocarcinoma

## Interventions

- **DRUG:** Erlotinib
- **OTHER:** Local Therapies

## Key facts

- **NCT ID:** NCT02450591
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-14
- **Primary completion:** 2017-12-11
- **Final completion:** 2017-12-11
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2018-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02450591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02450591, "Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02450591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*